Summary
Treatment with tamoxifen for 5 years has substantially reduced the risk of breast cancer recurrence and death throughout the first 15 years after diagnosis of estrogen receptor (ER)-positive early breast cancer [Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet 2011]. The Adjuvant Tamoxifen: Longer Against Shorter [ATLAS] trial compared the effects of continuing tamoxifen for a total of 10 years with stopping after the standard 5 years of treatment. This article presents data from the ATLAS trial on the effect of tamoxifen on 15-year survival [Davies C et al. Lancet 2012].
- Oncology Clinical Trials
- Breast Cancer
- © 2013 MD Conference Express®